Toby Maher

Director of ILD @KeckMedUSC. @imperialNHLI Honorary Prof of Interstitial Lung Disease and #IPF doctor. Working to #cureIPF

[ATS Blue Journal @ATSBlueEditor]

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial

Deupirfenidone slowed the rate of FVC decline compared with placebo in IPF

https://t.co/Bqk4xHlIym
@TobyMMaher
@atscommunity

[Naftali Kaminski @KaminskiMed]

The first snRNASeq & spatial transcriptomic analysis of bronchoscopic cryobiopsies from patients with Early IPF & preserved pulmonary functions is out on @biorxivpreprint and message is Early IPF is IPF‼️
https://t.co/yyX28bn7D2

[ATS Clinical Problems Assembly @ATSCPAssembly]

Feat: @TobyMMaher, Justin Oldham MD, and Marlies Wijsenbeek MD
Moderaters: @CarlaRCopeland and Ayodeji Adegunsoye MD
@ATS_Assemblies

[PeerView @PeerView]

Shoutout to @drcastelino, @tobymmaher, and Dr. Flaherty for leading an amazing discussion at #CHEST2025! Real-world takeaways for real-world care.

📺 Replay available here: https://t.co/kVyouNbpvq

Thanks to @Boehringer for their educational grant support #CME #MedEd

[PeerView @PeerView]

Watch Toby Maher, MD, MSc, PhD (@TobyMMaher), Flavia Castelino, MD (@drcastelino), and Kevin R. Flaherty, MD, MS discuss clearing the air on fibrosing ILDs at #CHEST2025 – to participate, visit: https://t.co/kVyouNbXkY https://t.co/aT4XRrm95f

[PeerView @PeerView]

Join Toby Maher, MD, MSc, PhD (@tobymmaher), Flavia Castelino, MD (@drcastelino), and Kevin R. Flaherty, MD, MS, on 10/21 at 6:00 AM CDT during #CHEST2025 for a #fibrosingILD #MedEd event.

🔗 https://t.co/kVyouNbpvq
#pulmonology

[Naftali Kaminski @KaminskiMed]

Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, even better drugs are on the way!!
Great day for #CureIPF
#ScienceMatters
https://t.co/edUy8DqUUJ

[Jen Silverman @SpeakJen]

⚡ Up your #fibrosingILD game! Join @PeerView + the experts Drs. Toby Maher (@tobymmaher) & Castelino (@drcastelino) at #CHEST2025 (Oct 21 | 6 AM CDT) for a rapid-fire TownHall on antifibrotics, immunomodulators & emerging therapies. 🫁
👉 https://t.co/icSA9ezpvE #MedEd

[Jen Silverman @SpeakJen]

🚨 Stay ahead in #fibrosingILD care! Join @PeerView with Drs. Maher (@tobymmaher) & Castelino (@drcastelino) at #CHEST2025 on 10/21 at 6 AM CDT for a TownHall on diagnosis, management & emerging therapies. Register: https://t.co/icSA9ezpvE #MedEd #pulmonology #ILD

[PeerView @PeerView]

"#FibrosingILD: Conversations on Timely Diagnosis and Antifibrotic Therapy” with Drs. Maher (@tobymmaher) & Castelino (@drcastelino). 10/21 at 6:00 AM CDT. https://t.co/kVyouNbpvq #CHEST2025 #pulmonology

[European Medical Journal @EMJReviews]

What do most clinicians miss about idiopathic pulmonary fibrosis?

Find out in the latest episode, where @doctor_saranya speaks with @TobyMMaher about what defines Interstitial Lung Disease, how idiopathic pulmonary fibrosis fits into the picture and more: https://t.co/a9VZFYyQ0t

[Phil Molyneaux @drphilmol]

Fantastic news for all our patients with IPF who suffer with cough! An overall 43% reduction in cough counts, similar improvement in patient reported cough and benefits seen in 2 weeks. We look forward to the phase 3 study!

[Naftali Kaminski @KaminskiMed]

When it rains it pours!! What an amazing #ATS2025 for #CurePF4ALL! Nerandomilast -> ⬇️FVC decline compared to placebo in Progressive Pulmonary Fibrosis patients on antifibrotics or untreated. 👏🏼 Drs Maher, Martinez & #FibroneerILD team!!
https://t.co/qhAmNZalCk

[Naftali Kaminski @KaminskiMed]

Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️FVC decline compared to placebo in patients on antifibrotics or untreated. Kudos Drs Richeldi and Wijsenbeek and #FibroneerIPF team https://t.co/ZRw5qwTlPc

[Toby Maher @TobyMMaher]

Great to see publication of the first positive phase 3 trial in patients with IPF. This represents an important step forward in the treatment of this terrible disease. #cureipf

[NEJM @NEJM]

Presented at #ATS2025:

In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: https://t.co/gjXxPWFpyR

@atscommunity

[Strados Labs @StradosLabs]

A reminder to tune in to our session at #ATS2025 on cough in pulmonary fibrosis. Join @TobyMMaher to discuss how new technologies and patient-reported outcomes can address this gap in IPF research.

Add to your calendar and join us! https://t.co/4XvCPMtIMC

#IPF #digitalhealth

[Respirology @RespirologyAPSR]

#ArtificialIntelligence and the Diagnosis of #InterstitialLungDisease: Are We Ready for ChatMDT?!
https://t.co/KnPwllwJ2y
an Editorial by @TobyMMaher on recent research:
https://t.co/F0V26Ekz2K

Follow us on Bluesky: @respirology.bsky.social

[Strados Labs @StradosLabs]

Join Strados Labs and @TobyMMaher at #ATS2025 for an engaging session on the often-overlooked symptom of cough in pulmonary fibrosis and ways we can address the gap.

May 19, 11:55 AM PST | Exhibitor Hall Innovation Hub #7

We look forward to seeing you there! #IPF

[Respirology @RespirologyAPSR]

Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non-Responders in IPF?
https://t.co/VD6dDe8OxZ
and Editorial by Toby Maher @tobymmaher on recent research:
https://t.co/2WhY0a0mY6

Follow us on Bluesky: @respirology.bsky.social

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Fibrosis: cross-organ biology and pathways to development of innovative drugs https://t.co/FY8SCQgvg2

This new Review highlights core pathways active in fibrotic conditions across organs, and proposes strategies to improve the translation of potential antifibrotic drugs